ENDO 2025 data shows anti-obesity medications restore hormone levels naturally. Here's what it means for you.
One of the most persistent complaints men have about aging — low testosterone — may have an unexpected solution. And it doesn't involve testosterone replacement therapy.
At ENDO 2025, the Endocrine Society's annual meeting in San Francisco, researchers presented data showing that GLP-1 medications normalized testosterone levels in 77% of men with obesity — up from just 53% at baseline. No TRT. No clomiphene. No HCG injections. Just GLP-1 therapy and the weight loss that came with it.
Dr. Shellsea Portillo Canales at SSM Health St. Louis University Hospital led the study, which tracked 110 adult men being treated with GLP-1 receptor agonists — specifically semaglutide (Ozempic/Wegovy), dulaglutide (Trulicity), and tirzepatide (Mounjaro/Zepbound). The average participant was 54 years old with a BMI of 35.
Critically, every man who was on testosterone replacement therapy, clomiphene, HCG, aromatase inhibitors, or any androgen supplement was excluded. This was about measuring what GLP-1 drugs do to testosterone on their own — with no hormonal assistance.
Over 18 months of treatment, participants lost an average of 10% of their body weight (about 26 pounds, from 255 to 229 pounds). Here's what happened to their hormones:
| Metric | Baseline | After 18 Months | Change |
|---|---|---|---|
| Total testosterone | 322 ng/dL | 380 ng/dL | +18% |
| Free testosterone | — | — | +17% |
| Men with normal T levels | 53% | 77% | +24 percentage points |
| Body weight | 255 lbs | 229 lbs | -10% |
Men with obesity have, on average, 30% lower testosterone than men at a healthy weight. This isn't a coincidence — it's biology. Here's the mechanism:
Excess visceral fat increases aromatase activity. Aromatase is the enzyme that converts testosterone into estradiol (estrogen). The more belly fat you carry, the more testosterone gets converted into estrogen, creating a hormonal double hit: less T, more E.
Insulin resistance disrupts the HPG axis. The hypothalamic-pituitary-gonadal axis — the signaling cascade that tells your body to produce testosterone — gets suppressed by chronic insulin resistance and inflammation. Obesity drives both.
Chronic inflammation tanks hormone production. Adipose tissue isn't just storage — it's an active endocrine organ that pumps out inflammatory cytokines. These directly impair Leydig cell function in the testes, where testosterone is made.
GLP-1 medications attack all three mechanisms simultaneously. By reducing visceral fat, improving insulin sensitivity, and decreasing systemic inflammation, they create the conditions for your body's natural testosterone production to recover — without externally supplying hormones.
This data doesn't mean TRT is unnecessary for everyone. Men with severe hypogonadism caused by pituitary or testicular disorders (primary or secondary hypogonadism from non-obesity causes) still need direct testosterone replacement.
But for the large population of men whose low T is driven by obesity and metabolic dysfunction — which describes the majority of men diagnosed with "low T" at men's health clinics — the GLP-1 data suggests a potentially better first step.
Why? Because TRT comes with real trade-offs that GLP-1 therapy avoids:
This study is observational, not a randomized controlled trial. It can't prove that GLP-1 medications directly caused the testosterone improvement — only that the two occurred together. The testosterone increases (18% for total T) are more modest than what direct TRT delivers, and for men with severely low levels, they may not be sufficient.
The study also had a relatively small sample size (110 men), and the population was 80% White, limiting generalizability. Larger, more diverse randomized trials are needed to confirm causality.
Still, the directional signal is strong and consistent with prior research showing that weight loss from bariatric surgery also normalizes testosterone. GLP-1s appear to produce the same endocrine benefit through pharmacological weight loss.
Explore providers offering semaglutide and tirzepatide — the same medications used in this research.
Compare Providers →If you're a man with obesity and symptoms of low testosterone — fatigue, low libido, difficulty building muscle, brain fog — consider this:
Before starting TRT, ask your doctor about GLP-1 therapy first. Losing 10% of your body weight may restore your testosterone naturally, without the fertility trade-offs, dependency, and monitoring requirements of hormone replacement.
And if you're already on TRT and wondering whether you still need it — this research suggests that significant weight loss could eventually allow some men to discontinue exogenous testosterone as their natural production recovers.
The ENDO 2025 data represents one of the strongest signals yet that GLP-1 medications aren't just weight-loss drugs — they're metabolic restoration tools. For men, the testosterone normalization finding is particularly significant because it addresses one of the most common and frustrating symptoms of obesity without adding another medication to the mix.
77% of men achieving normal testosterone levels through weight loss alone. That's not a side effect — that's a reason to start.